Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Therachon logo — Life-Transforming Therapies - Developing novel therapeutics...

Therachon

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions

Founded 2014 Switzerland Switzerland 1 employees Series B Total: $100.00M Biotechnology, Health and Wellness

General Information

Company Name Therachon
Founded Year 2014
Location Switzerland Switzerland +1
Employees 1
Industries Biotechnology, Health and Wellness
Funding Stage Series B
Social

Get notified when Therachon moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Therachon

Therachon, a Switzerland-based biopharmaceutical company, is dedicated to developing and commercializing innovative therapies for severe rare conditions with significant unmet medical needs. The company's lead product candidate, apraglutide, holds promise as a potentially best-in-class synthetic peptide analog of glucagon-like peptide-2 (GLP-2) and is currently undergoing evaluation in two Phase 2 clinical trials for the treatment of short bowel syndrome (SBS). SBS is a malabsorption disorder resulting from the loss of functional small intestine. Therachon's second product candidate, TA-46, targets achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans and has completed a Phase 1 clinical trial. The company's efforts are aligned with addressing gastrointestinal and musculoskeletal disorders, demonstrating a commitment to tackling challenging medical conditions. With a founding year of 2014, Therachon's recent progress includes a substantial $60.00M Series B investment in August 2018, which attracted notable investors such as Novo Holdings, Bpifrance, OrbiMed, Versant Ventures, Cowen Digital, Tekla Capital, Inserm Transfert Initiative, and Pfizer Venture Investments. In summary, Therachon is a company making significant strides in the field of biotechnology, with a strong focus on rare conditions and a promising pipeline. The recent Series B investment reflects the confidence of reputable investors in the company's potential and its ability to bring life-transforming therapies to market.

Taxonomy: biopharmaceutical company, rare genetic diseases, clinical stage, therapeutics, novel treatments, malabsorption disorder, glucagon-like peptide-2, Phase 2 clinical trials, achondroplasia, short-limbed dwarfism, global biotechnology, protein therapy, Switzerland, France

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 8
Investor Investor Investor Investor Investor Investor
•••• •••• 		09 Aug 2018
Series A •••••• 2
Investor Investor
06 Jan 2017
Series A •••••• - 30 Sep 2015

Therachon Alternatives & Competitors

Therachon vs
Entera Bio Ltd.
Entera Bio Ltd.

Developing innovative oral delivery of therapeutic proteins.

Post Ipo Equity
19 employees
Biopharma, Biotechnology
Therachon vs
Endevica Bio
Endevica Bio United States

Reversing cachexia and improving quality of life in cancer patients. Phase 1 trial underway.

Series B
20 employees
Biotechnology, Health and Wellness
Therachon vs
DNAtrix
DNAtrix United States

DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer....

Series Unknown
3 employees
Biotechnology, Health Care

FAQ About Therachon

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions
Therachon was founded in 2014.
Therachon is headquartered in Switzerland.
Therachon operates in the following industries: Biotechnology, Health and Wellness.
Therachon has approximately 1 employees.
Therachon has completed 3 funding rounds, raising a total of $100.00M. The latest funding stage is Series B.
Top alternatives and competitors to Therachon include Entera Bio Ltd., Endevica Bio, DNAtrix, Himuka AM Pharma / Himuka AM Australia, Wilson Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Therachon and Entera Bio Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Therachon and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy